Rice Hall James & Associates LLC Purchases 18,706 Shares of Omnicell, Inc. $OMCL

Rice Hall James & Associates LLC grew its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 47.7% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 57,936 shares of the company’s stock after purchasing an additional 18,706 shares during the quarter. Rice Hall James & Associates LLC owned about 0.13% of Omnicell worth $1,764,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Lazard Asset Management LLC boosted its stake in Omnicell by 3.8% during the 2nd quarter. Lazard Asset Management LLC now owns 1,708,345 shares of the company’s stock valued at $50,225,000 after purchasing an additional 62,733 shares during the period. Sumitomo Mitsui Trust Group Inc. lifted its holdings in shares of Omnicell by 1.3% during the second quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,423,604 shares of the company’s stock worth $41,854,000 after buying an additional 17,680 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Omnicell by 2.6% in the second quarter. Geode Capital Management LLC now owns 1,195,896 shares of the company’s stock valued at $35,163,000 after acquiring an additional 30,678 shares during the period. Qube Research & Technologies Ltd grew its stake in shares of Omnicell by 38.4% in the second quarter. Qube Research & Technologies Ltd now owns 653,971 shares of the company’s stock worth $19,227,000 after acquiring an additional 181,394 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Omnicell by 1.7% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 461,506 shares of the company’s stock worth $13,568,000 after acquiring an additional 7,518 shares during the last quarter. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Price Performance

NASDAQ:OMCL opened at $46.40 on Friday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.21 and a current ratio of 1.44. The company has a 50-day moving average of $37.87 and a 200-day moving average of $33.01. Omnicell, Inc. has a 52 week low of $22.66 and a 52 week high of $47.69. The company has a market capitalization of $2.08 billion, a price-to-earnings ratio of 107.91, a PEG ratio of 5.08 and a beta of 0.83.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Zacks Research downgraded shares of Omnicell from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 9th. Benchmark upped their price objective on shares of Omnicell from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Omnicell in a research report on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $43.00.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.